Q4 Results 2022: Jindal Stainless, Alembic Pharma, Mahindra Holidays announce March quarter results; here are key highlights

Q4 Results 2022: As the earnings season is ongoing, more companies announced their March quarter results. Among the Nifty50 companies, Britannia Industries Limited and HDFC Limited announced their quarterly earnings. Other top companies which declared their results included Jindal Stainless Ltd, Alembic Pharma, Mahindra Holidays and TARC Ltd. Here are key highlights of the results.

JSL Q4 Results 2022: net profit jumps over two-fold to Rs 750 cr

Jindal Stainless Ltd (JSL) on Monday posted a 156 per cent jump in consolidated net profit at Rs 749.88 crore for the March quarter, mainly on account of higher income.

In the year-ago quarter, its net profit stood at Rs 292.61 crore, the company said in a regulatory filing.

Total income in January-March 2022 rose to Rs 6,582.84 crore, from Rs 3,926.30 crore in the same quarter of 2020-21.

Total expenses were at Rs 5,885.19 crore during the quarter under review, compared to Rs 3,564.82 crore earlier.

In a separate statement, JSL said it has maintained a strong performance on the back of adaptive strategies in supply chain and product basket management.

"Despite volatility and global disruptions in raw material supply and logistics, the company effectively doubled its exports sales proportion to 32 per cent of total sales volumes in Q4 FY22 as compared to 16 per cent Q4FY21, with a keen focus on the value-added product segments," it said.

The ongoing Russia-Ukraine unrest adversely impacted the global supply chain and commodity prices. While on the domestic front, the Chinese and Indonesian imports of subsidized stainless steel products continued to disrupt the Indian market, the statement said.

It is estimated that imports from China and Indonesia rose by 147 per cent and 280 per cent respectively in FY22 over the corresponding period last year.

JSL MD Abhyuday Jindal said, "JSL's strategic decision to focus on export sales and strengthen its niche value added product portfolio resulted in a robust performance. This also enabled the company to steer through certain challenging segments in the domestic market that faced subsidized imports from China and Indonesia."

"We are also proactively switching from thermal to renewable energy infrastructure at our plant premises, and are working towards our goal of net zero carbon emissions by 2050," he added.

Jindal had recently told PTI that his company is keen to make an investment in the renewable energy sector to set up 300 MW solar and wind capacities in Rajasthan, Haryana and Odisha. 

Jindal Stainless shares ended at Rs 179.80 on the NSE on Monday, down by 1.7 per cent from the Friday closing price.

Alembic Pharma Q4 Results 2022: consolidated PAT at Rs 35 cr,  revenues up at Rs 1,416 cr

Alembic Pharmaceuticals on Monday reported a consolidated profit after tax (PAT) of Rs 35 crore for the fourth quarter ended March 2022.

The company said the PAT is post charging off non-recurring expense of Rs 188 crore.

The drug firm had reported a PAT of Rs 251 crore in the January-March quarter of 2020-21 fiscal, Alembic Pharmaceuticals said in a statement.

Revenue from operations rose to Rs 1,416 crore for the fourth quarter of 2021-22, compared to Rs 1,280 crore in the year-ago period.

For the year ended March 31, 2022, the company reported a consolidated PAT of Rs 546 crore as against Rs 1,178 crore in 2020-21.

Revenue from operations for the last fiscal also declined to Rs 5,306 crore from Rs 5,393 crore earlier.

"India branded business continues to deliver strong market beating growth in Q4. India business witnessed market outperforming growth across most of the products and therapy areas," Alembic

Pharmaceuticals Managing Director Shaunak Amin noted.

The company said its US generics business grew 17 per cent in the fourth quarter to Rs 557 crore.

The drug firm said its board has recommended a dividend of Rs 10 each (500 per cent) per share having face value of Rs 2 each, subject to approval of the shareholders.

Shares of the company settled 0.29 per cent up at Rs 783.80 apiece on the BSE.

Alembic Pharmaceuticals shares ended at Rs 786.80 on the NSE on Monday, up by 0.7 per cent from the Friday closing price.

See Zee Business Live TV Streaming Below:

Mahindra Holidays Q4 Results 2022: Mahindra Holidays and Resorts reports profit after tax at Rs 15.87 crore in Q4

Mahindra Holidays and Resorts India Ltd on Monday reported its consolidated profit after tax at Rs 15.87 crore in the fourth quarter ended March 31, 2022.

The company had posted a consolidated loss after tax of Rs 9.73 crore in the same period of previous fiscal, Mahindra Holidays and Resorts India Ltd (MHRIL) said in a regulatory filing.

Consolidated revenue from operations during the period under review stood at Rs 542.58 crore as against Rs 465.41 crore in the year-ago quarter, it added.

Total expenditure during the fourth quarter stood at Rs 551.03 crore as against Rs 507.03 crore in the corresponding period of the previous fiscal.

For the year ended March 31, 2022, consolidated profit after tax was at Rs 67.64 crore. It had posted a consolidated loss after tax of Rs 14 crore in the preceding fiscal, the company said.

The company said its resort occupancies were at 77 per cent in the fourth quarter, close to pre-pandemic levels, while for the full year it was at 74 per cent.

MHRIL said its member additions for the quarter were at 4,058, resulting in a total of 12,764 members during the year. The cumulative member base stands at around 2.66 lakh.

During the year, the company said it achieved a milestone of over 4,500 rooms with a gross addition of 385 rooms, taking its total inventory count to 4,568 rooms.

MHRIL's managing director and CEO Kavinder Singh said, "Despite the Omicron wave, we have delivered a strong Q4 with highest ever resort income, growth in margins and profit before tax (PBT)."

At a full year level, he said, "We have delivered exceptional performance with healthy growth in member additions, occupancies, income, PBT and cash position. Our resort count has increased to 84 and our room count crosses the 4,500 mark."

On European operations, Singh added, "Despite multiple COVID-19 waves severally impacting our European subsidiary Holiday Club Resorts (HCR) during the year, HCR delivered close to break-even EBITDA demonstrating the strength of its business model. In periods when restrictions were eased off, HCR recovery was strong and rapid."

On the outlook, he said, "Domestic leisure travel remains strong and the outlook is positive for FY23."

Mahindra Holidays shares ended at Rs 259.50 on the NSE on Monday, up by 1.7 per cent from the Friday closing price.

Inputs from PTI